Partial antagonist-Olanzapine LA

From Psychiatrienet
Revision as of 15:59, 29 October 2021 by Ken (talk | contribs) (Created page with "{{Drugswitch | from = Partial antagonist | header = partialantagonist | to = Olanzapine_LA | stop = * '''Week 1-6:''' {{Cont}} * '''Week 7:''' {{Stop}} | start = {{StartDepo...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Partial antagonist

Aripiprazole
Brexpiprazole
Cariprazine

Olanzapine
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Olanzapine
EMEA zypadhera
PubChem 4585
PubMed Olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine

Switch medication from Partial antagonist to Olanzapine_LA.[1] [2]
Partial antagonist is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'partial antagonist' group from anotherdrug should be read as partial antagonist-anotherdrug. Similarly, a switch from a member of the 'partial antagonist' group to anotherdrug should be read as anotherdrug-partial antagonist.

Nietinrijdenbord.png Stop Partial antagonist
  • Week 1-6: Continue drug at usual dose
  • Week 7: Stop drug
Eenrichtingbord.png Start Olanzapine_LA
  • Day 1: Start depot according general dosing advice (Dotted line in graph)
Letopbord.png Cave
Infobord.png More information
StopArip7WeeksStartDepot.jpg
Nietinrijdenbord.png — Partial antagonist
Eenrichtingbord.png — Olanzapine_LA


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.